169 related articles for article (PubMed ID: 38542016)
21. Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis.
Hwang J; Yoon HM; Lee BH; Kim PH; Kim KW
Neurology; 2022 Mar; 98(9):e938-e946. PubMed ID: 35017312
[TBL] [Abstract][Full Text] [Related]
22. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Cardiac Function by Echocardiographic Global Longitudinal Strain in a Cohort of Children with Neurofibromatosis Type 1 Treated with Selumetinib.
Caiffa T; Tessitore A; Magnolato A; Petz M; Bobbo M; Chicco D; D'Agata Mottolese B; Porcari A; Barbi E; Sinagra G; Bruno I
Paediatr Drugs; 2023 Mar; 25(2):217-224. PubMed ID: 36529809
[TBL] [Abstract][Full Text] [Related]
24. Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing.
Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Raghunathan A; Schwartz J; Spinner RJ
J Neurooncol; 2024 May; ():. PubMed ID: 38739187
[TBL] [Abstract][Full Text] [Related]
25. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis.
Han Y; Li B; Yu X; Liu J; Zhao W; Zhang D; Zhang J
J Neurol; 2024 May; 271(5):2379-2389. PubMed ID: 38502338
[TBL] [Abstract][Full Text] [Related]
27. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1.
Prada CE; Rangwala FA; Martin LJ; Lovell AM; Saal HM; Schorry EK; Hopkin RJ
J Pediatr; 2012 Mar; 160(3):461-7. PubMed ID: 21996156
[TBL] [Abstract][Full Text] [Related]
28. Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.
Osum SH; Coutts AW; Duerre DJ; Tschida BR; Kirstein MN; Fisher J; Bell WR; Delpuech O; Smith PD; Widemann BC; Moertel CL; Largaespada DA; Watson AL
Neurooncol Adv; 2021; 3(1):vdab020. PubMed ID: 33978635
[TBL] [Abstract][Full Text] [Related]
29. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
Gross AM; Dombi E; Widemann BC
Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
[TBL] [Abstract][Full Text] [Related]
30. Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells.
Attiah B; Alewine G; Easter MK; Coover RA; Fahrenholtz CD
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543265
[TBL] [Abstract][Full Text] [Related]
31. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
[TBL] [Abstract][Full Text] [Related]
32. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J; Onar-Thomas A; Young Poussaint T; Wu S; Ligon AH; Lindeman N; Banerjee A; Packer RJ; Kilburn LB; Goldman S; Pollack IF; Qaddoumi I; Jakacki RI; Fisher PG; Dhall G; Baxter P; Kreissman SG; Stewart CF; Jones DTW; Pfister SM; Vezina G; Stern JS; Panigrahy A; Patay Z; Tamrazi B; Jones JY; Haque SS; Enterline DS; Cha S; Fisher MJ; Doyle LA; Smith M; Dunkel IJ; Fouladi M
Lancet Oncol; 2019 Jul; 20(7):1011-1022. PubMed ID: 31151904
[TBL] [Abstract][Full Text] [Related]
33. Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national real-world case series.
Coltin H; Perreault S; Larouche V; Black K; Wilson B; Vanan MI; Gupta AA; Morgenstern DA; Parkin PC; Bouffet E; Ramaswamy V
Pediatr Blood Cancer; 2022 Aug; 69(8):e29633. PubMed ID: 35289492
[TBL] [Abstract][Full Text] [Related]
34. Plexiform Neurofibroma Without Neurofibromatosis Type 1.
Wollina U; Schönlebe J
Acta Dermatovenerol Croat; 2020 Dec; 28(7):245-246. PubMed ID: 33835000
[TBL] [Abstract][Full Text] [Related]
35. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
37. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
[TBL] [Abstract][Full Text] [Related]
39. Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline.
Volontè M; Isoletta E; Gordon S; Foiadelli T; Bassanese F; Rossi A; Marseglia GL; Savasta S; Brazzelli V
Dermatol Ther; 2022 Aug; 35(8):e15607. PubMed ID: 35638252
[No Abstract] [Full Text] [Related]
40. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]